News summary

Cambrian Bio reports weight-loss drug data from Phase 1 trials

Source: Longevity Technology • Published: 16 Nov 2026, 11:36

Summarized by Masters of Longevity from Longevity Technology.

Phase 1 studies reported safety and preliminary weight‑loss effects for ATX‑304.

Cambrian Bio reports weight-loss drug data from Phase 1 trials
Key Takeaways
  • Cambrian Bio reported Phase 1 safety and early weight loss.
  • ATX‑304 Phase 1 results were generally tolerable in participants.
  • Early signals from ATX‑304 support advancing to larger trials.
Read the full article at Longevity Technology ↗

Continue exploring

Recommended MoL Picks

MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickApoB: The cholesterol signal LDL can missIn longevity medicine, the useful biomarkers are not always the exotic ones. ApoB is a relatively simple blood test that can sharpen cardiovascular prevention when LDL-C looks reassuring but particle burden remains high.